文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

磁共振引导全腺体挽救性高剂量率前列腺近距离放疗的长期前瞻性研究结果

Long-Term Outcomes of a Prospective Study on Magnetic Resonance Imaging-Guided Whole-Gland Salvage High-Dose-Rate Prostate Brachytherapy for Locally Recurrent Prostate Cancer.
PubMed 文献 · Adv Radiat Oncol · 2026-08-21

中位随访72.0个月,仅1例(3.3%)3级及以上毒性;3年与5年生化无进展生存率分别为73.0%和24.8%,5年免雄激素剥夺治疗率为69.6%。

要点

  • 全腺体挽救性HDR近距离放疗耐受性好,仅1例(3.3%)晚期3级泌尿毒性。
  • 3年与5年生化无进展生存率分别为73.0%和24.8%,5年免ADT率为69.6%。
  • 23例生化复发中18例(78%)证实为靶区局部失败。

核心结论

  • 磁共振引导全腺体挽救性HDR近距离放疗联合前列腺内靶区加量耐受性良好,治疗后进展与局部失败相关。

主要发现

  • 中位随访72.0个月(10.7-121.5个月),93%患者初始EBRT为常规分割。
  • 挽救性HDR前中位PSA为3.67 ng/mL(0.56-11.01 ng/mL),7例(23.3%)行PSMA PET分期。
  • 4例(13%)需临时导尿,仅1例(3.3%)出现3-5级毒性(晚期3级泌尿毒性)。
  • 3年PSA无进展生存率和免ADT率分别为73.0%和93.0%,5年分别为24.8%和69.6%。
  • 26例复查HDR后MR(中位415天)中9例(35%)有持续病灶;23例(77%)PSA复发者中18例(78%)经MR、PSMA PET或靶向活检证实靶区病变。

关键数值与推荐

  • 处方剂量为整个前列腺21 Gy、MR定义的前列腺内靶区27 Gy,分2次植入、间隔1-2周。
  • 未使用辅助雄激素剥夺治疗。

临床怎么用

  • 对于既往外照射放疗后MR可见的局部复发前列腺癌,可考虑全腺体挽救性HDR近距离放疗联合前列腺内靶区加量。
  • 治疗后PSA进展者应重点评估靶区局部失败,必要时行MR、PSMA PET或靶向活检确认。

局限性

  • 随访期间PSA无进展生存率随时间明显下降,长期疗效仍需更大队列验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Whole-gland salvage high-dose-rate (HDR) prostate brachytherapy is an emerging option for radiorecurrent prostate cancer. However, long-term prospective data remain limited. This report presents the long-term results of our prospective study on the toxicities, health-related quality of life, and efficacy of whole-gland HDR prostate brachytherapy. METHODS AND MATERIALS: Patients with biopsy-confirmed, magnetic resonance (MR)-visible local recurrent prostate cancer after previous external beam radiation therapy (EBRT) were eligible. Patients underwent MR-assisted, ultrasound-based whole-gland HDR prostate brachytherapy with a prescription dose of 21 Gy to the entire prostate and 27 Gy to the MR-defined intraprostatic target volume (TV) divided over 2 implants separated by 1 to 2 weeks. Adjuvant androgen deprivation therapy was not used. RESULTS: Thirty patients were enrolled in the study. Median follow-up from salvage HDR was 72.0 months (10.7-121.5 months). Most patients (93%) had initial EBRT doses at conventional fractionation. The pre-HDR median prostate-specific antigen was 3.67 ng/mL (0.56-11.01 ng/mL). Seven (23.3%) were staged with prostate-specific membrane antigen positron emission tomography. Four (13%) required temporary urinary catheterization. There was only 1 (3.3%) grade 3 to 5 toxicity-a late grade 3 genitourinary toxicity. The prostate-specific antigen progression-free survival and freedom from androgen deprivation therapy rates were 73.0% and 93.0% at 3 years, and 24.8% and 69.6% at 5 years, respectively. Of the 26 patients who had a post-HDR MR imaging (median, 415 days), 9 (35%) had persistent disease. Of the 23 (77%) patients who had prostate-specific antigen relapse, 18 (78%) patients had disease at the TV confirmed by MR imaging, prostate-specific membrane antigen positron emission tomography, or targeted biopsy. CONCLUSIONS: Whole-gland salvage HDR brachytherapy with intraprostatic boost is well tolerated. Progression after salvage treatment was associated with local failure.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Hu HP, Morton G, Loblaw A, et al. Long-Term Outcomes of a Prospective Study on Magnetic Resonance Imaging-Guided Whole-Gland Salvage High-Dose-Rate Prostate Brachytherapy for Locally Recurrent Prostate Cancer. Adv Radiat Oncol. 2026. PMID: 42935525. doi:10.1016/j.adro.2026.102168

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。